Compare TRIP & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRIP | NRIX |
|---|---|---|
| Founded | 2000 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2011 | 2020 |
| Metric | TRIP | NRIX |
|---|---|---|
| Price | $15.19 | $19.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | $15.88 | ★ $26.77 |
| AVG Volume (30 Days) | ★ 2.1M | 1.9M |
| Earning Date | 11-06-2025 | 01-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 124.53 | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $1,891,000,000.00 | $83,687,000.00 |
| Revenue This Year | $5.18 | $58.38 |
| Revenue Next Year | $5.08 | N/A |
| P/E Ratio | $25.90 | ★ N/A |
| Revenue Growth | 4.25 | ★ 48.32 |
| 52 Week Low | $10.43 | $8.18 |
| 52 Week High | $20.16 | $22.50 |
| Indicator | TRIP | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 49.86 | 64.51 |
| Support Level | $14.89 | $19.02 |
| Resistance Level | $15.73 | $22.50 |
| Average True Range (ATR) | 0.49 | 1.20 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 56.02 | 45.99 |
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2024, 52% of revenue came from the company's core Brand Tripadvisor segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of sales in 2024, and TheFork, its dining brand, represented 10% of revenue (about 8% of sales were intersegment, which are eliminated from consolidated revenue).
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.